Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 4/20 | 0.42 |
| ▸ | CNR2 | P34972 | 2/20 | 0.41 |
| ▸ | SMO | Q99835 | 2/20 | 0.39 |
| ▸ | KLRK1 | P26718 | 2/20 | 0.35 |
| ▸ | MICA | Q29983 | 2/20 | 0.35 |
| ▸ | RAET1L | Q5VY80 | 2/20 | 0.35 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 4/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14545044 | 0.91 | CNR1 (0.43) | CNR1CNR2SMOKLRK1MICA | |
| SCHEMBL14523455 | 0.89 | GPBAR1 (0.45) | CNR1CNR2SMOGPBAR1 | |
| SCHEMBL14545073 | 0.88 | CNR1 (0.41) | CNR1CNR2SMOKLRK1MICA | |
| SCHEMBL14545075 | 0.88 | CNR1 (0.40) | CNR1CNR2SMOUSP30FAAH | |
| SCHEMBL5519690 | 0.84 | CNR1 (0.53) | CNR1CNR2SMOGPBAR1SLC22A12 | |
| SCHEMBL4695173 | 0.79 | CNR1 (0.51) | CNR1CNR2SMO | |
| SCHEMBL5516071 | 0.76 | CNR1 (0.56) | CNR1CNR2DPP4 | |
| SCHEMBL14545420 | 0.74 | CNR1 (0.51) | CNR1CNR2FAAH | |
| SCHEMBL14545423 | 0.74 | CNR1 (0.53) | CNR1CNR2SMOKLRK1MICA | |
| SCHEMBL14545099 | 0.74 | CNR1 (0.57) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070078135-A1 | Substituted heteroaryl CB1 antagonists | NEUROGEN CORPORATION (US) | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078135-A1 | Substituted heteroaryl CB1 antagonists | CNR1, CNR2, OPRL1 | CNR1 1/4885CNR2 2/4885SMO 840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.